Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk January 9, 2025
Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results November 4, 2024
